Pablo Zubiaur Precioso-rekin lankidetzan egindako argitalpenak (3)

2024

  1. Use of Exposure Data to Establish Causality in Drug–Adverse Event Relationships: An Example with Desvenlafaxine

    Pharmaceuticals, Vol. 17, Núm. 1

2023

  1. Genetic Variation in CYP2D6 and SLC22A1 Affects Amlodipine Pharmacokinetics and Safety

    Pharmaceutics, Vol. 15, Núm. 2

2022

  1. Polymorphism of Drug Transporters, Rather Than Metabolizing Enzymes, Conditions the Pharmacokinetics of Rasagiline

    Pharmaceutics, Vol. 14, Núm. 10